159 related articles for article (PubMed ID: 30372722)
1. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
2. Painful nipple hyperkeratosis secondary to vemurafenib.
Carr ES; Brown SC; Fiala KH
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
[TBL] [Abstract][Full Text] [Related]
3. Facial spiny follicular hyperkeratosis induced by vemurafenib.
Nieto Rodríguez D; Gómez Fernández C; Rueda Carnero JM
J Dermatol; 2018 Feb; 45(2):e43-e44. PubMed ID: 28971523
[No Abstract] [Full Text] [Related]
4. Vemurafenib-induced DRESS.
Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
[No Abstract] [Full Text] [Related]
5. RASopathic alopecia: hair changes associated with vemurafenib therapy.
Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
[No Abstract] [Full Text] [Related]
6. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
[No Abstract] [Full Text] [Related]
7. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
9. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
10. Toxic epidermal necrolysis induced by vemurafenib.
Lapresta A; Dotor A; González-Herrada C
Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
[No Abstract] [Full Text] [Related]
11. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
12. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
13. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
15. Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
Bhangoo MS; Saven A
Leuk Lymphoma; 2019 May; 60(5):1331-1333. PubMed ID: 30322325
[No Abstract] [Full Text] [Related]
16. Multiple eruptive squamous cell carcinomas: a possible clinical sign in melanoma patients treated with vemurafenib.
Jovic A; Tiodorovic D; Popovic D; Vidovic N; Zlatanovic Z; Cekic S; Kocic H; Damiani G
Eur J Dermatol; 2021 Apr; 31(2):279-280. PubMed ID: 34001482
[No Abstract] [Full Text] [Related]
17. Vemurafenib-associated keratoses with genetic heterogeneity of RAS.
Loh E; Hosler GA
J Drugs Dermatol; 2014 Apr; 13(4):495-7. PubMed ID: 24719071
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
[No Abstract] [Full Text] [Related]
19. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
